1431 related articles for article (PubMed ID: 28353286)
1. Interaction of LRRK2 and α-Synuclein in Parkinson's Disease.
Daher JP
Adv Neurobiol; 2017; 14():209-226. PubMed ID: 28353286
[TBL] [Abstract][Full Text] [Related]
2. The role of posttranslational modifications of α-synuclein and LRRK2 in Parkinson's disease: Potential contributions of environmental factors.
Pajarillo E; Rizor A; Lee J; Aschner M; Lee E
Biochim Biophys Acta Mol Basis Dis; 2019 Aug; 1865(8):1992-2000. PubMed ID: 30481588
[TBL] [Abstract][Full Text] [Related]
3. LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons.
Henderson MX; Peng C; Trojanowski JQ; Lee VMY
Acta Neuropathol Commun; 2018 May; 6(1):45. PubMed ID: 29855356
[TBL] [Abstract][Full Text] [Related]
4. Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble α-synuclein in neurons.
Schapansky J; Khasnavis S; DeAndrade MP; Nardozzi JD; Falkson SR; Boyd JD; Sanderson JB; Bartels T; Melrose HL; LaVoie MJ
Neurobiol Dis; 2018 Mar; 111():26-35. PubMed ID: 29246723
[TBL] [Abstract][Full Text] [Related]
5. The unlikely partnership between LRRK2 and α-synuclein in Parkinson's disease.
Cresto N; Gardier C; Gubinelli F; Gaillard MC; Liot G; West AB; Brouillet E
Eur J Neurosci; 2019 Feb; 49(3):339-363. PubMed ID: 30269383
[TBL] [Abstract][Full Text] [Related]
6. G2019S-LRRK2 Expression Augments α-Synuclein Sequestration into Inclusions in Neurons.
Volpicelli-Daley LA; Abdelmotilib H; Liu Z; Stoyka L; Daher JP; Milnerwood AJ; Unni VK; Hirst WD; Yue Z; Zhao HT; Fraser K; Kennedy RE; West AB
J Neurosci; 2016 Jul; 36(28):7415-27. PubMed ID: 27413152
[TBL] [Abstract][Full Text] [Related]
7. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein.
Lin X; Parisiadou L; Gu XL; Wang L; Shim H; Sun L; Xie C; Long CX; Yang WJ; Ding J; Chen ZZ; Gallant PE; Tao-Cheng JH; Rudow G; Troncoso JC; Liu Z; Li Z; Cai H
Neuron; 2009 Dec; 64(6):807-27. PubMed ID: 20064389
[TBL] [Abstract][Full Text] [Related]
8. LRRK2 and neurodegeneration.
Santpere G; Ferrer I
Acta Neuropathol; 2009 Mar; 117(3):227-46. PubMed ID: 19142648
[TBL] [Abstract][Full Text] [Related]
9. Pathological Functions of LRRK2 in Parkinson's Disease.
Jeong GR; Lee BD
Cells; 2020 Nov; 9(12):. PubMed ID: 33266247
[TBL] [Abstract][Full Text] [Related]
10. Mutations in LRRK2 impair NF-κB pathway in iPSC-derived neurons.
López de Maturana R; Lang V; Zubiarrain A; Sousa A; Vázquez N; Gorostidi A; Águila J; López de Munain A; Rodríguez M; Sánchez-Pernaute R
J Neuroinflammation; 2016 Nov; 13(1):295. PubMed ID: 27863501
[TBL] [Abstract][Full Text] [Related]
11. Parkinson's Disease-Associated LRRK2 Interferes with Astrocyte-Mediated Alpha-Synuclein Clearance.
Streubel-Gallasch L; Giusti V; Sandre M; Tessari I; Plotegher N; Giusto E; Masato A; Iovino L; Battisti I; Arrigoni G; Shimshek D; Greggio E; Tremblay ME; Bubacco L; Erlandsson A; Civiero L
Mol Neurobiol; 2021 Jul; 58(7):3119-3140. PubMed ID: 33629273
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of the p53-p21 pathway by G2019S LRRK2 contributes to the cellular senescence and accumulation of α-synuclein.
Ho DH; Seol W; Son I
Cell Cycle; 2019 Feb; 18(4):467-475. PubMed ID: 30712480
[TBL] [Abstract][Full Text] [Related]
13. LRRK2 modifies α-syn pathology and spread in mouse models and human neurons.
Bieri G; Brahic M; Bousset L; Couthouis J; Kramer NJ; Ma R; Nakayama L; Monbureau M; Defensor E; Schüle B; Shamloo M; Melki R; Gitler AD
Acta Neuropathol; 2019 Jun; 137(6):961-980. PubMed ID: 30927072
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Exposure to PFE-360 in the AAV-α-Synuclein Rat Model: Findings and Implications.
Andersen MA; Sotty F; Jensen PH; Badolo L; Jeggo R; Smith GP; Christensen KV
eNeuro; 2019; 6(6):. PubMed ID: 31685675
[TBL] [Abstract][Full Text] [Related]
15. Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation.
Giordana MT; D'Agostino C; Albani G; Mauro A; Di Fonzo A; Antonini A; Bonifati V
Mov Disord; 2007 Jan; 22(2):275-8. PubMed ID: 17149743
[TBL] [Abstract][Full Text] [Related]
16. Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration.
Daher JP; Abdelmotilib HA; Hu X; Volpicelli-Daley LA; Moehle MS; Fraser KB; Needle E; Chen Y; Steyn SJ; Galatsis P; Hirst WD; West AB
J Biol Chem; 2015 Aug; 290(32):19433-44. PubMed ID: 26078453
[TBL] [Abstract][Full Text] [Related]
17. α-Synuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of Parkinson disease.
Covy JP; Giasson BI
Neurotoxicology; 2011 Oct; 32(5):622-9. PubMed ID: 21238487
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of LRRK2 kinase activity promotes anterograde axonal transport and presynaptic targeting of α-synuclein.
Brzozowski CF; Hijaz BA; Singh V; Gcwensa NZ; Kelly K; Boyden ES; West AB; Sarkar D; Volpicelli-Daley LA
Acta Neuropathol Commun; 2021 Nov; 9(1):180. PubMed ID: 34749824
[TBL] [Abstract][Full Text] [Related]
19. LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation.
Zhao Y; Keshiya S; Perera G; Schramko L; Halliday GM; Dzamko N
Neurobiol Dis; 2020 Oct; 144():105049. PubMed ID: 32800998
[TBL] [Abstract][Full Text] [Related]
20. LRRK2, alpha-synuclein, and tau: partners in crime or unfortunate bystanders?
Outeiro TF; Harvey K; Dominguez-Meijide A; Gerhardt E
Biochem Soc Trans; 2019 Jun; 47(3):827-838. PubMed ID: 31085616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
